Global Lichen Nitidus Treatment Market Overview
Lichen Nitidus Treatment Market Size was valued at USD 0.79 Billion in 2023. The Global Lichen Nitidus Treatment industry is projected to grow from USD 0.85 Billion in 2024 to USD 1.59 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.30% during the forecast period (2024 - 2032). Lichen nitidus is a rare, chronic skin disease characterized by flat-topped, and skin-colored micropapules. Characteristics of these micropapules are the size, shape (pin point), color, location and itching. It mostly affects geriatric and pediatric population. They commonly occur on the chest, abdomen, arms and genital areas, including the penis. In this disease, T lymphocytes get activated resulting in the formation of these micropapules. In lichen nitidus, linear arrangement of micropapules can be seen on the fore arm or affected area.
Increasing prevalence of skin diseases across the globe is the major factor contributing the growth of the market. Unawareness about rare skin diseases among people may act as a restrain for the market growth.
Global Lichen Nitidus Treatment Market Segmentation
The lichen nitidus treatment market is segmented on the basis of types, which includes oral and topical treatment. On the basis of treatment, the market is segmented into corticosteroids, retinoid, antihistamines, phototherapy and other treatment. On the basis of end user, the market is segmented into hospitals, dermatology clinics, and others.
Regional Analysis of the Lichen Nitidus Treatment Market
The Americas accounts for the largest share of the lichen nitidus treatment market due to increasing prevalence of skin disease, availability of treatment methods at affordable cost and demand for new topical products for its treatment. According to the American Osteopathic College of Dermatology, the number of people suffering from lichen nitidus is increasing at a steady rate in American countries. It also stated that in 2013, USD 75 billion were spent on the treatment of various skin diseases. Aging population is another factor responsible for the market growth in these countries.
Europe is the second largest market that holds a noticeable share of the lichen nitidus treatment market owing to an increase in the awareness regarding skin diseases, demand for skin care cosmetics, and growing market for dermatology in many European countries.
In Asia Pacific, the market is driven by increasing in number of dermatology clinics, rising demand for evidence based skin care and increasing prevalence of diseases associated with lichen nitidus such as atopic dermatitis and tuberculosis.
The Middle East & Africa is expected to show a steady but positive growth in this market due constant demand for diagnostics services in dermatology, rising awareness about lichen nitidus among children and its prevention.
Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Intended Audience
- Medical Device Manufacturers
- Medical Device Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Key Players in the Lichen Nitidus Treatment Market
- Pfizer Inc. (U.S)
- Novartis AG (Switzerland)
- Merck Sharp & Dohme Corp.
- Merck & Co., Inc. (U.S)
- Sanofi (France)
- GlaxoSmithKline plc. (U.K)
- AstraZeneca (U.K)
- Hubei Gedian Humanwell Pharmaceutical Co.,Ltd (China)
- Farmabios SPA (Italy)
- Horizon Pharma plc. (Ireland)
The report on the lichen nitidus treatment market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the Lichen Nitidus Treatment Market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions
Report Attribute/Metric
|
Details
|
Market Size
|
USD 1.59 Million by 2032
|
CAGR
|
 9.30% (2024-2032)
|
Base Year
|
  2021
|
Forecast Period
|
  2024-2032
|
Historical Data
|
  2020
|
Forecast Units
|
 Value (USD Million)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
Segments Covered
|
Types, end user, Region
|
Geographies Covered
|
America, Europe, Asia Pacific, Middle East & Africa
|
Key Vendors
|
Pfizer Inc. (U.S), Novartis AG (Switzerland), Merck Sharp & Dohme Corp., Merck & Co., Inc. (U.S), Sanofi (France), GlaxoSmithKline plc. (U.K), AstraZeneca (U.K), Hubei Gedian Humanwell Pharmaceutical Co.,Ltd (China), Farmabios SPA (Italy), Horizon Pharma plc. (Ireland)
|
Lichen Nitidus Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The CAGR would be 9.30% for the forecast period (2024-2032).
Increasing cases of skin diseases play a crucial role in the Lichen Nitidus Treatment Market.
The Lichen Nitidus Treatment Market would USD 1.59 Billion by 2032.
The Americas would drive the Lichen Nitidus Treatment Market ahead.
Retinoid, antihistamines, phototherapy, corticosteroids, and other treatment segments that have been discussed in the report.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report